Document Detail


A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas.
MedLine Citation:
PMID:  15070664     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Patients with peripheral T-cell lymphomas (PTLs) have an extremely poor prognosis when relapsed or refractory to conventional chemotherapy. We have studied alemtuzumab, a humanized anti-CD52 monoclonal antibody, as therapy for patients with heavily pretreated and refractory PTL. Fourteen patients entered the study. All had clinical stage III or IV disease. Patients received a rapidly escalating dosage of alemtuzumab during the first week and, thereafter, 30 mg intravenously 3 times per week for a maximum of 12 weeks. Trimethoprim/sulphamethoxazole and valaciclovir prophylaxis was given to all patients. The overall response rate was 36% (5 of 14). Three patients achieved a complete remission (CR) and 2 patients a partial remission. The durations of the CRs were 2, 6, and 12 months, respectively. Toxicity included cytomegalovirus reactivation in 6 patients, which was successfully treated with ganciclovir or foscarnet; pulmonary aspergillosis in 2 patients; and pancytopenia in 4 patients. Epstein-Barr virus-related hemophagocytosis was observed in 2 patients. Five patients died of causes related to the treatment, in combination with advanced disease. We conclude that alemtuzumab is active when used in patients with advanced, heavily pretreated PTL, although it is associated with significant hematologic toxicity and infectious complications. Further studies are warranted in younger patients and patients with less advanced disease.
Authors:
Gunilla Enblad; Hans Hagberg; Martin Erlanson; Jeanette Lundin; Anja Porwit MacDonald; Roland Repp; Johannes Schetelig; Gernot Seipelt; Anders Osterborg
Related Documents :
15468344 - An efficient therapeutic approach to patients with acute promyelocytic leukemia using a...
18094594 - Characteristics of acute myeloid leukemia without hla-dr expression.
11298594 - Sensitivity to the abl inhibitor sti571 in fresh leukaemic cells obtained from chronic ...
9753054 - The expression of co-stimulatory molecules and their relationship to the prognosis of h...
24001414 - Oxidative stress in patients with scalp seborrheic dermatitis.
15546074 - An open, randomized, controlled trial of penicillin, doxycycline, and cefotaxime for pa...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't     Date:  2003-12-30
Journal Detail:
Title:  Blood     Volume:  103     ISSN:  0006-4971     ISO Abbreviation:  Blood     Publication Date:  2004 Apr 
Date Detail:
Created Date:  2004-04-08     Completed Date:  2004-05-27     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  7603509     Medline TA:  Blood     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2920-4     Citation Subset:  AIM; IM    
Affiliation:
Department of Oncology, Uppsala University Hospital, Uppsala, Sweden. gunilla.enblad@onkologi.uu.se
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Antibodies, Monoclonal / adverse effects,  therapeutic use*
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm / adverse effects,  therapeutic use*
Bone Marrow / drug effects
Drug Resistance, Neoplasm
Female
Humans
Infection / etiology
Lymphoma, T-Cell, Peripheral / drug therapy*
Male
Middle Aged
Pilot Projects
Recurrence
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antibodies, Neoplasm; 3A189DH42V/alemtuzumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hemochromatosis mutations in the general population: iron overload progression rate.
Next Document:  Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy ...